JP2018522053A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522053A5 JP2018522053A5 JP2018506137A JP2018506137A JP2018522053A5 JP 2018522053 A5 JP2018522053 A5 JP 2018522053A5 JP 2018506137 A JP2018506137 A JP 2018506137A JP 2018506137 A JP2018506137 A JP 2018506137A JP 2018522053 A5 JP2018522053 A5 JP 2018522053A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- composition
- tlr4 agonist
- pharmaceutical composition
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 16
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 16
- 239000000556 agonist Substances 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 15
- 239000002246 antineoplastic agent Substances 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- -1 combination Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 229940041181 antineoplastic drug Drugs 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000012635 anticancer drug combination Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- REEGNIYAMZUTIO-MGSMBCBTSA-N (2s)-2-[[(3r)-3-decanoyloxytetradecanoyl]amino]-3-[(2r,3r,4r,5s,6r)-3-[[(3r)-3-decanoyloxytetradecanoyl]amino]-4-[(3r)-3-decanoyloxytetradecanoyl]oxy-6-(hydroxymethyl)-5-phosphonooxyoxan-2-yl]oxypropanoic acid Chemical compound CCCCCCCCCCC[C@@H](OC(=O)CCCCCCCCC)CC(=O)N[C@H](C(O)=O)CO[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCC)[C@H]1NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCC REEGNIYAMZUTIO-MGSMBCBTSA-N 0.000 claims 1
- ICLAYQQKWJGHBV-XJZMHMBSSA-N (2s)-2-[[(3r)-3-decoxytetradecanoyl]amino]-3-[(2r,3r,4r,5s,6r)-3-[[(3r)-3-decoxytetradecanoyl]amino]-4-[(3r)-3-decoxytetradecanoyl]oxy-6-(hydroxymethyl)-5-phosphonooxyoxan-2-yl]oxypropanoic acid Chemical compound CCCCCCCCCCC[C@@H](OCCCCCCCCCC)CC(=O)N[C@H](C(O)=O)CO[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OCCCCCCCCCC)[C@H]1NC(=O)C[C@@H](CCCCCCCCCCC)OCCCCCCCCCC ICLAYQQKWJGHBV-XJZMHMBSSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 150000008271 glucosaminides Chemical class 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562201912P | 2015-08-06 | 2015-08-06 | |
| US62/201,912 | 2015-08-06 | ||
| PCT/IB2016/053290 WO2017021792A1 (en) | 2015-08-06 | 2016-06-03 | Tlr4 agonists and compositions thereof and their use in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018522053A JP2018522053A (ja) | 2018-08-09 |
| JP2018522053A5 true JP2018522053A5 (enExample) | 2019-07-04 |
Family
ID=56121139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506137A Pending JP2018522053A (ja) | 2015-08-06 | 2016-06-03 | Ｔｌｒ４アゴニストおよびその組成物ならびに癌の処置におけるそれらの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10765690B2 (enExample) |
| EP (1) | EP3331565A1 (enExample) |
| JP (1) | JP2018522053A (enExample) |
| KR (1) | KR20180032642A (enExample) |
| CN (1) | CN108136024A (enExample) |
| AU (1) | AU2016303387B2 (enExample) |
| BR (1) | BR112018002520A2 (enExample) |
| CA (1) | CA2994790A1 (enExample) |
| RU (1) | RU2018107930A (enExample) |
| WO (1) | WO2017021792A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
| BR112020016314A2 (pt) | 2018-02-12 | 2020-12-15 | Inimmune Corporation | Compostos ou um sais farmaceuticamente aceitáveis, composição farmacêutica, kit, e, métodos para elicitar, intensificar ou modificar uma resposta imunológica, para tratar, prevenir ou reduzir a suscetibilidade a câncer, para tratar, prevenir ou reduzir a suscetibilidade a uma doença infecciosa, para tratar, prevenir ou reduzir a suscetibilidade a uma alergia, para tratar, prevenir ou reduzir a suscetibilidade a uma afecção autoimune, para tratar, prevenir ou reduzir a suscetibilidade em um sujeito à infecção bacteriana, viral, priônica, autoimunidade, câncer ou alergia, para tratar, prevenir ou reduzir a suscetibilidade à autoimunidade, alergia, reperfusão de isquemia ou sepse, para tratar, prevenir ou reduzir a gravidade de ataques epiléticos e para tratar, prevenir ou reduzir a suscetibilidade a doenças oculares como degeneração macular, hipertensão ocular e infecção ocular |
| WO2020007760A1 (en) * | 2018-07-03 | 2020-01-09 | Glaxosmithkline Intellectual Property Development Limited | Tlr4 compounds or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions or formulations, methods of preparation, treatment or uses |
| WO2020031087A1 (en) * | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| AU2021380287A1 (en) * | 2020-11-11 | 2023-06-22 | Daiichi Sankyo Company, Limited | Novel aminoalkyl glucosaminide 4-phosphate derivative |
| CN118453877A (zh) * | 2023-08-04 | 2024-08-09 | 中国人民解放军海军军医大学 | 小分子化合物组合在制备启动肝脏原位再生药物中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| ATE395923T1 (de) | 2000-05-19 | 2008-06-15 | Corixa Corp | Prophylaktische und therapeutische behandlung von infektiösen, autoimmunen und allergischen krankheiten mit verbindungen, die auf monosacchariden basieren |
| EP1311522B1 (en) | 2000-08-04 | 2006-03-22 | Corixa Corporation | New immunoeffector compounds |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| US6525028B1 (en) | 2002-02-04 | 2003-02-25 | Corixa Corporation | Immunoeffector compounds |
| US7030094B2 (en) * | 2002-02-04 | 2006-04-18 | Corixa Corporation | Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21 |
| US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
| US7288640B2 (en) | 2002-07-08 | 2007-10-30 | Corixa Corporation | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor |
| US7960522B2 (en) * | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| WO2005040229A2 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| US8629116B2 (en) * | 2008-12-23 | 2014-01-14 | Glaxosmithkline Biologicals S.A. | Method for inducing a TRIF-bias |
| ES2629337T3 (es) * | 2009-02-09 | 2017-08-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos |
| WO2011150258A1 (en) * | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
| US20120321694A1 (en) | 2010-10-27 | 2012-12-20 | Daniel Larocque | Compositions and uses |
| GB201101331D0 (en) * | 2011-01-26 | 2011-03-09 | Glaxosmithkline Biolog Sa | Compositions and uses |
| EP2986303B1 (en) * | 2013-04-18 | 2020-02-26 | Immune Design Corp. | Gla monotherapy for use in cancer treatment |
-
2016
- 2016-06-03 BR BR112018002520A patent/BR112018002520A2/pt not_active Application Discontinuation
- 2016-06-03 RU RU2018107930A patent/RU2018107930A/ru not_active Application Discontinuation
- 2016-06-03 JP JP2018506137A patent/JP2018522053A/ja active Pending
- 2016-06-03 AU AU2016303387A patent/AU2016303387B2/en not_active Ceased
- 2016-06-03 US US15/749,854 patent/US10765690B2/en not_active Expired - Fee Related
- 2016-06-03 CN CN201680058161.3A patent/CN108136024A/zh active Pending
- 2016-06-03 WO PCT/IB2016/053290 patent/WO2017021792A1/en not_active Ceased
- 2016-06-03 CA CA2994790A patent/CA2994790A1/en not_active Abandoned
- 2016-06-03 EP EP16729070.9A patent/EP3331565A1/en not_active Withdrawn
- 2016-06-03 KR KR1020187005943A patent/KR20180032642A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522053A5 (enExample) | ||
| TN2017000511A1 (en) | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them. | |
| JP2019521180A5 (enExample) | ||
| WO2015081133A3 (en) | Nucleotides for the treatment of liver cancer | |
| JP2013503174A5 (enExample) | ||
| CL2016001629A1 (es) | Compuestos tricíclicos como agentes anticancerígenos | |
| NZ739902A (en) | Multiligand agent for drug delivery | |
| JP2019508440A5 (enExample) | ||
| WO2016080810A3 (ko) | 바이구아나이드 화합물 및 이의 용도 | |
| GEAP202215088A (en) | Magl inhibitors | |
| EP4011871A3 (en) | Processes for preparing oxathiazin-like compounds | |
| EA201370103A1 (ru) | Соединения и композиции для лечения рака | |
| EA202090978A1 (ru) | Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции | |
| ME02119B (me) | Spojevi korisni za inhibiranje chk1 | |
| MX2024006074A (es) | Inhibidor de parp1 selectivo y aplicacion del mismo. | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| PH12017500810A1 (en) | Substituted 2,4 diamino-quinoline as new anticancer agents | |
| JP2013541586A5 (enExample) | ||
| GEAP202115056A (en) | CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | |
| WO2016130581A3 (en) | Combination cancer therapy | |
| RU2019105574A (ru) | Противоопухолевый агент, усилитель противоопухолевого действия и противоопухолевый набор | |
| WO2015193517A3 (en) | Liquid pharmaceutical composition comprising pemetrexed | |
| CO6341557A2 (es) | Derivados nitrogenados de la pancratistatina | |
| NI202100031A (es) | Formulación basada en ciclodextrina de un inhibidor de bcl-2 | |
| AU2018244925A1 (en) | Compositions for the treatment of drug-resistant tumors and methods of use thereof |